225 related articles for article (PubMed ID: 37230214)
1. Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD.
Park SH; Helsley RN; Fadhul T; Willoughby JLS; Noetzli L; Tu HC; Solheim MH; Fujisaka S; Pan H; Dreyfuss JM; Bons J; Rose J; King CD; Schilling B; Lusis AJ; Pan C; Gupta M; Kulkarni RN; Fitzgerald K; Kern PA; Divanovic S; Kahn CR; Softic S
Metabolism; 2023 Aug; 145():155591. PubMed ID: 37230214
[TBL] [Abstract][Full Text] [Related]
2. Fructose Induced KHK-C Increases ER Stress and Modulates Hepatic Transcriptome to Drive Liver Disease in Diet-Induced and Genetic Models of NAFLD.
Park SH; Helsley RN; Fadhul T; Willoughby JLS; Noetzli L; Tu HC; Solheim MH; Fujisaka S; Pan H; Dreyfuss JM; Bons J; Rose J; King CD; Schilling B; Lusis AJ; Pan C; Gupta M; Kulkarni RN; Fitzgerald K; Kern PA; Divanovic S; Kahn CR; Softic S
bioRxiv; 2023 Jan; ():. PubMed ID: 36747758
[TBL] [Abstract][Full Text] [Related]
3. Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation.
Helsley RN; Park SH; Vekaria HJ; Sullivan PG; Conroy LR; Sun RC; Romero MDM; Herrero L; Bons J; King CD; Rose J; Meyer JG; Schilling B; Kahn CR; Softic S
J Hepatol; 2023 Jul; 79(1):25-42. PubMed ID: 36822479
[TBL] [Abstract][Full Text] [Related]
4. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
Softic S; Cohen DE; Kahn CR
Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
[TBL] [Abstract][Full Text] [Related]
5. Fructose and hepatic insulin resistance.
Softic S; Stanhope KL; Boucher J; Divanovic S; Lanaspa MA; Johnson RJ; Kahn CR
Crit Rev Clin Lab Sci; 2020 Aug; 57(5):308-322. PubMed ID: 31935149
[TBL] [Abstract][Full Text] [Related]
6. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling.
Softic S; Gupta MK; Wang GX; Fujisaka S; O'Neill BT; Rao TN; Willoughby J; Harbison C; Fitzgerald K; Ilkayeva O; Newgard CB; Cohen DE; Kahn CR
J Clin Invest; 2017 Nov; 127(11):4059-4074. PubMed ID: 28972537
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction.
Gutierrez JA; Liu W; Perez S; Xing G; Sonnenberg G; Kou K; Blatnik M; Allen R; Weng Y; Vera NB; Chidsey K; Bergman A; Somayaji V; Crowley C; Clasquin MF; Nigam A; Fulham MA; Erion DM; Ross TT; Esler WP; Magee TV; Pfefferkorn JA; Bence KK; Birnbaum MJ; Tesz GJ
Mol Metab; 2021 Jun; 48():101196. PubMed ID: 33667726
[TBL] [Abstract][Full Text] [Related]
8. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity.
Papadopoulos G; Legaki AI; Georgila K; Vorkas P; Giannousi E; Stamatakis G; Moustakas II; Petrocheilou M; Pyrina I; Gercken B; Kassi E; Chavakis T; Pateras IS; Panayotou G; Gika H; Samiotaki M; Eliopoulos AG; Chatzigeorgiou A
Metabolism; 2023 Jul; 144():155552. PubMed ID: 36996933
[TBL] [Abstract][Full Text] [Related]
9. Ketohexokinase knockout mice, a model for essential fructosuria, exhibit altered fructose metabolism and are protected from diet-induced metabolic defects.
Miller CO; Yang X; Lu K; Cao J; Herath K; Rosahl TW; Askew R; Pavlovic G; Zhou G; Li C; Akiyama TE
Am J Physiol Endocrinol Metab; 2018 Sep; 315(3):E386-E393. PubMed ID: 29870677
[TBL] [Abstract][Full Text] [Related]
10. Fructose consumption as a risk factor for non-alcoholic fatty liver disease.
Ouyang X; Cirillo P; Sautin Y; McCall S; Bruchette JL; Diehl AM; Johnson RJ; Abdelmalek MF
J Hepatol; 2008 Jun; 48(6):993-9. PubMed ID: 18395287
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin resistance and proinflammatory changes in the visceral adipose tissue induced by fructose consumption via ketohexokinase-dependent pathway.
Marek G; Pannu V; Shanmugham P; Pancione B; Mascia D; Crosson S; Ishimoto T; Sautin YY
Diabetes; 2015 Feb; 64(2):508-18. PubMed ID: 25187370
[TBL] [Abstract][Full Text] [Related]
12. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.
Shepherd EL; Saborano R; Northall E; Matsuda K; Ogino H; Yashiro H; Pickens J; Feaver RE; Cole BK; Hoang SA; Lawson MJ; Olson M; Figler RA; Reardon JE; Nishigaki N; Wamhoff BR; Günther UL; Hirschfield G; Erion DM; Lalor PF
JHEP Rep; 2021 Apr; 3(2):100217. PubMed ID: 33490936
[TBL] [Abstract][Full Text] [Related]
13. The small intestine shields the liver from fructose-induced steatosis.
Jang C; Wada S; Yang S; Gosis B; Zeng X; Zhang Z; Shen Y; Lee G; Arany Z; Rabinowitz JD
Nat Metab; 2020 Jul; 2(7):586-593. PubMed ID: 32694791
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.
Kazierad DJ; Chidsey K; Somayaji VR; Bergman AJ; Birnbaum MJ; Calle RA
Med; 2021 Jul; 2(7):800-813.e3. PubMed ID: 35590219
[TBL] [Abstract][Full Text] [Related]
15. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
[TBL] [Abstract][Full Text] [Related]
16. Fructose as a key player in the development of fatty liver disease.
Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
[TBL] [Abstract][Full Text] [Related]
17. Both isoforms of ketohexokinase are dispensable for normal growth and development.
Diggle CP; Shires M; McRae C; Crellin D; Fisher J; Carr IM; Markham AF; Hayward BE; Asipu A; Bonthron DT
Physiol Genomics; 2010 Nov; 42A(4):235-43. PubMed ID: 20841500
[TBL] [Abstract][Full Text] [Related]
18. A luminescence-based protocol for assessing fructose metabolism via quantification of ketohexokinase enzymatic activity in mouse or human hepatocytes.
Park SH; Helsley RN; Noetzli L; Tu HC; Wallenius K; O'Mahony G; Boucher J; Liu J; Softic S
STAR Protoc; 2021 Sep; 2(3):100731. PubMed ID: 34409309
[TBL] [Abstract][Full Text] [Related]
19. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y
J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387
[TBL] [Abstract][Full Text] [Related]
20. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
Jensen T; Abdelmalek MF; Sullivan S; Nadeau KJ; Green M; Roncal C; Nakagawa T; Kuwabara M; Sato Y; Kang DH; Tolan DR; Sanchez-Lozada LG; Rosen HR; Lanaspa MA; Diehl AM; Johnson RJ
J Hepatol; 2018 May; 68(5):1063-1075. PubMed ID: 29408694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
